Gemina Laboratories Ltd. (GLABF)
USD 0.92
(17.08%)
USD 0.92
(17.08%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -5.17 Million CAD | 12.72% |
| 2023 | -5.92 Million CAD | -26.42% |
| 2022 | -4.69 Million CAD | -640.41% |
| 2021 | -633.51 Thousand CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -1.69 Million CAD | 13.03% |
| 2024 FY | - CAD | 13.92% |
| 2024 Q4 | -1.01 Million CAD | -19.82% |
| 2024 Q3 | -858.64 Thousand CAD | 45.77% |
| 2024 Q2 | -1.55 Million CAD | 7.85% |
| 2023 Q4 | -1.94 Million CAD | -56.55% |
| 2023 Q1 | -767.69 Thousand CAD | 40.73% |
| 2023 Q2 | -1.97 Million CAD | -157.56% |
| 2023 FY | - CAD | -26.42% |
| 2023 Q3 | -1.24 Million CAD | 37.21% |
| 2022 Q3 | -1.5 Million CAD | -100.18% |
| 2022 Q2 | -753.43 Thousand CAD | 33.62% |
| 2022 Q1 | -1.13 Million CAD | -157.08% |
| 2022 FY | - CAD | -640.41% |
| 2022 Q4 | -1.29 Million CAD | 14.12% |
| 2021 FY | - CAD | 0.0% |
| 2021 Q2 | - CAD | 0.0% |
| 2021 Q3 | -1063.00 CAD | 0.0% |
| 2021 Q4 | -441.48 Thousand CAD | -41431.8% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Capstone Therapeutics Corp. | -1.74 Million USD | -195.761% |
| Skye Bioscience, Inc. | -13.54 Million USD | 61.795% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 105.504% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 1081.323% |
| Qrons Inc. | -40.08 Thousand USD | -12813.398% |
| Adynxx, Inc. | - USD | Infinity% |
| BioStem Technologies, Inc. | -7.55 Million USD | 31.479% |
| CSL Limited | 4.78 Billion USD | 100.108% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 70.203% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -33.249% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -452.412% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 90.647% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -1309.456% |
| Rebus Holdings, Inc. | -951 Thousand USD | -444.25% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -718.433% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 67.386% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 92.714% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 12.702% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -2064.256% |
| SQZ Biotechnologies Company | -64.14 Million USD | 91.931% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -95.724% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -236.957% |
| Mesoblast Limited | -62.38 Million USD | 91.704% |
| Marizyme, Inc. | -34.28 Million USD | 84.902% |
| Genus plc | 73.7 Million USD | 107.023% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 21.715% |
| Pharming Group N.V. | 9.87 Million USD | 152.403% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -247.975% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -45.921% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 40.996% |
| ContraFect Corporation | -64.99 Million USD | 92.037% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -14.353% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -269.225% |
| IMV Inc. | -35.52 Million USD | 85.43% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -122.729% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -899.104% |
| ONE Bio Corp. | 13.61 Million USD | 138.021% |
| Accustem Sciences Inc. | -3.74 Million USD | -38.154% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 89.268% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -308.467% |
| Q BioMed Inc. | -617.62 Thousand USD | -738.016% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 244.9% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -126.564% |
| Biomind Labs Inc. | -1.03 Million USD | -400.297% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 86.942% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -78.95% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 27.725% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 77075.297% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -20603.276% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -106.87% |
| GB Sciences, Inc. | -1.41 Million USD | -264.524% |
| Alpha Cognition Inc. | -9.7 Million USD | 46.672% |
| HST Global, Inc. | -5303.00 USD | -97501.716% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -151.62% |
| Halberd Corporation | -74.27 Thousand USD | -6868.078% |
| Enzolytics Inc. | -2.12 Million USD | -143.909% |
| Agentix Corp. | -1.37 Million USD | -277.313% |
| Resverlogix Corp. | -11.74 Million USD | 55.92% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -68.978% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -216.02 Million USD | 97.604% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 525.293% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 158.459% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -245.306% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 1466.214% |
| AVAX Technologies, Inc. | -6.11 Million USD | 15.326% |
| Zenith Capital Corp. | -8.6 Million USD | 39.858% |
| Genscript Biotech Corporation | -248.71 Million USD | 97.919% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -29610.229% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -111.564% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -2840.399% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -169.446% |
| Kadimastem Ltd | -2.62 Million USD | -97.221% |
| Helix BioMedix, Inc. | -1.04 Million USD | -394.673% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -2758.179% |
| LadRx Corporation | 412.28 Thousand USD | 1355.404% |
| Cell Source, Inc. | -4.27 Million USD | -21.142% |
| Regen BioPharma, Inc. | 1.46 Million USD | 453.068% |
| NovAccess Global Inc. | -1.03 Million USD | -400.177% |
| Affymax, Inc. | -14.29 Million USD | 63.793% |
| Itoco Inc. | -1.86 Million USD | -176.931% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -1263.421% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -363.783% |
| Mobile Lads Corp. | -2.24 Million USD | -130.944% |
| CytoDyn Inc. | -18.02 Million USD | 71.292% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -6449.265% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -42224.139% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -965.689% |
| SYBLEU INC | -141.57 Thousand USD | -3555.988% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -387.361% |
| International Stem Cell Corporation | 202 Thousand USD | 2662.287% |
| Bioxytran, Inc. | -3.82 Million USD | -35.487% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -9732.483% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -110.234% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 85.57% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -11401.82% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -89.036% |
| Neutra Corp. | -181.24 Thousand USD | -2755.672% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 74.325% |
| PureTech Health plc | -11.62 Million USD | 55.484% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 74.323% |
| IXICO plc | -707 Thousand USD | -632.082% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 32.65% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 89.294% |
| CSL Limited | 4.73 Billion USD | 100.109% |
| Cellectis S.A. | -92.63 Million USD | 94.413% |